COMMUNIQUÉS West-GlobeNewswire

Intelligent Bio Solutions Completes Clinical Cut-off Study, Advances FDA 510(k) Clinical Program Targeting Multi-Billion-Dollar U.S. Drug Screening Market
02/04/2026
Study results finalized on schedule support FDA clearance and planned U.S. commercial launch Company advances second phase of clinical program for 510(k) submission with method comparison, usability, and interference [...]
MDIC appoints Philips Chief Medical Officer Carla Goulart Peron as new board member
02/04/2026
April 2, 2026 Amsterdam, the Netherlands – Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, today announced that Carla Goulart Peron, MD, Chief Medical Officer at Philips, has been appointed [...]
Revolution Medicines Begins Treating Patients in Phase 3 RASolute 303 Trial Evaluating Daraxonrasib as First Line Treatment for Patients with Metastatic Pancreatic Cancer
02/04/2026
REDWOOD CITY, Calif., April 02, 2026 (GLOBE NEWSWIRE) -- Revolution Medicines, a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced that it has [...]
Sienna Announces First Quarter 2026 Results Release Date and Conference Call
02/04/2026
MARKHAM, Ontario, April 02, 2026 (GLOBE NEWSWIRE) -- Sienna Senior Living Inc. (“ Sienna ” or the “ Company ”) (TSX: SIA) announced that it will report its 2026 first quarter results after market close on Tuesday, May 5 [...]
Bionano Announces Publication from Johns Hopkins and MD Anderson Showing that OGM can Outperform Traditional Methods in Analysis of Multiple Myeloma
02/04/2026
SAN DIEGO, April 02, 2026 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) announced the publication of a study in the American Journal of Hematology demonstrating that optical genome mapping (OGM) can [...]
Dr. Joseph Mikhael Steps into New Role as Medical Advisor for the International Myeloma Foundation
02/04/2026
STUDIO CITY, Calif., April 02, 2026 (GLOBE NEWSWIRE) -- The International Myeloma Foundation (IMF) today announced that Joseph Mikhael, MD, MEd, FRCPC, FACP, FASCO has taken the step of transitioning his role as Chief [...]
PracticeLink Reveals Evolved Brand Identity Focused on Clarity, Simplicity and Trust for Healthcare Providers and Recruiters
02/04/2026
Updated identity reflects a clearer standard for what clinicians and hiring teams can expect—delivered steadily instead of disruptively ST. LOUIS and HINTON, West Virginia, April 02, 2026 (GLOBE NEWSWIRE) -- [...]
Emergent BioSolutions Participates in Upcoming International Preparedness Conferences
02/04/2026
GAITHERSBURG, Md., April 02, 2026 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS), a global life sciences leader with biodefense and medical countermeasures products, announced today that members of its [...]
Cartesian Therapeutics Announces New Employment Inducement Grants
02/04/2026
FREDERICK, Md., April 02, 2026 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (the “Company”), a late clinical-stage biotechnology company pioneering cell therapy for autoimmune diseases, today [...]
Prenetics Announces NBA Champion and Two-Time MVP Giannis Antetokounmpo as IM8 Global Partner and Shareholder in Multi-Year Partnership
02/04/2026
Giannis becomes the first NBA athlete shareholder in a NASDAQ-listed health and longevity brand, joining the fastest supplement company ever to reach $100M ARR in just 11 months Giannis unlocks 35 million followers [...]
MIMEDX to Sponsor Leading Advanced Wound Care Conferences
02/04/2026
Multispecialty Focus with Industry Leadership Aimed at Improving Patient Outcomes Company Will Feature Recent Additions to Its Advanced Wound Care Portfolio MARIETTA, Ga., April 02, 2026 (GLOBE NEWSWIRE) -- MiMedx Group [...]
Entera Bio Announces Pricing of $10.0 Million Direct Investment by BVF Partners with Potential for up to $24.5 Million in Total Proceeds
02/04/2026
TEL AVIV, Israel, April 02, 2026 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (Nasdaq: ENTX) (“Entera” or the “Company”), a leader in the development of oral peptides, today announced that it has entered into a securities [...]
Catalyst MedTech Announces Acquisition of X3D
02/04/2026
Expands OEM Platform and Strengthens Leadership in Nuclear Medicine Imaging PITTSBURGH, April 02, 2026 (GLOBE NEWSWIRE) -- Catalyst MedTech, a national leader in nuclear medicine and molecular imaging solutions, today [...]
Tvardi Therapeutics to Participate in the Raymond James Biotech Innovation Symposium
02/04/2026
HOUSTON, April 02, 2026 (GLOBE NEWSWIRE) -- Tvardi Therapeutics, Inc. (“Tvardi”) (NASDAQ: TVRD), a clinical-stage biopharmaceutical company focused on the development of novel, oral, small molecule therapies targeting [...]
Annovis Secures U.S. Patent for Buntanetap in the Prevention and Treatment of Neurological Injuries Caused by Brain Infections
02/04/2026
MALVERN, Pa., April 02, 2026 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a Phase 3 clinical-stage biotechnology company developing the investigational oral therapy, buntanetap, for [...]
Protecting Healthy Futures: Unity Consortium Urges Families to Prioritize Adolescent Health During Immunization Action Week
02/04/2026
AIAW26 Runs April 6-10, Highlights the Critical Role of Well-Visits and AAP-Recommended Immunizations VENTNOR CITY, N.J., April 02, 2026 (GLOBE NEWSWIRE) -- Unity® Consortium, a non-profit dedicated to adolescent and [...]
Calidi Biotherapeutics to Present New Data on Its Lead Asset CLD-401 at the AACR Annual Meeting in April 2026
02/04/2026
SAN DIEGO, April 02, 2026 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics, Inc. (NYSE American: CLDI) (“Calidi” or the “Company”), a biotechnology company pioneering the development of targeted genetic medicines, will [...]
Onconetix Highlights Realbotix AI Humanoid Robot Delivery Update
02/04/2026
Realbotix Announces Expected Delivery of 19 Robots in March, April, and May 2026 as it Scales Production Capacity; Onconetix recently Entered into a Definitive Agreement to Acquire Realbotix LLC, a subsidiary of [...]
Priovant Expands Brepocitinib Development Program with New Phase 2b/3 Trial in Lichen Planopilaris (LPP)
02/04/2026
Lichen planopilaris (LPP) is a highly morbid inflammatory scalp disorder that causes generally irreversible scarring hair loss, often accompanied by profound pain, itch, and burning sensations; no FDA-approved therapies [...]

Pages